Synlogic, Inc. earnings releases SYBX

Annual Quarterly

Synlogic, Inc. last reported quarterly results on Nov 12, 2024, for Q3 FY2024 (the quarter ended Sep 30, 2024): revenue of $0 (-100.0% year over year) and diluted EPS of -$0.01. It usually reports 39–44 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 39–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
Nov 12, 2024 43 days after quarter end	Q3 FY2024 ended Sep 30, 2024	0 -100.0%	-0 +99.0%	-0.01 +99.6%
Aug 8, 2024 39 days after quarter end	— ended Jun 30, 2024	—	—	—
May 14, 2024 44 days after quarter end	— ended Mar 31, 2024	—	—	—
Feb 12, 2024 43 days after quarter end	— ended Dec 31, 2023	—	—	—
Nov 9, 2023 40 days after quarter end	— ended Sep 30, 2023	—	—	—
Aug 10, 2023 41 days after quarter end	— ended Jun 30, 2023	—	—	—
May 11, 2023 41 days after quarter end	— ended Mar 31, 2023	—	—	—
Nov 10, 2022 41 days after quarter end	— ended Sep 30, 2022	—	—	—

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: SYBX (OTC)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Winchester, MA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1527599
Former names: Mirna Therapeutics, Inc. (until Aug 25, 2017)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.